Document is current
Any future updates will be listed below
-
Authors
Ma, Li
Wang, Long
Chang, Lijia
Shan, Jiajing
Qu, Youge
Wang, Xingming
Wan, Xiayun
Fujita, Yuko
Hashimoto, Kenji https://orcid.org/0000-0002-8892-0439
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20dm0107119)
MEXT | Japan Society for the Promotion of Science (21H02846)
National Natural Science Foundation of China (81772044)
- License Information
-
More Information
Article History
Received: 11 August 2022
Revised: 8 September 2022
Accepted: 16 September 2022
First Online: 28 September 2022
Conflict of interest
: Dr. K. Hashimoto is the inventor of filed patent applications on “The use of R-Ketamine in the treatment of psychiatric diseases”, “(S)-norketamine and salt thereof as pharmaceutical”, “R-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “R-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. K. Hashimoto has also received speakers’ honoraria, consultant fee, or research support from Abbott, Meiji Seika Pharma, Seikagaku Corporation, Sumitomo Pharma, Taisho, Otsuka, Murakami Farm and Perception Neuroscience. Other authors declare no conflict of interest.
